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Abstract  1 
Background Hyperkalemia is prevalent in end-stage renal disease patients, being 2 
involved in life-threatening arrhythmias. Although polystyrene sulfonate (PS) is 3 
commonly used for the treatment of hyperkalemia, direct comparison of effects between 4 
calcium and sodium PS (CPS and SPS) on mineral and bone metabolism has not yet 5 
been studied. Methods In a randomized and crossover design, 20 pre-dialysis patients 6 
with hyperkalemia (>5 mmol/l) received either oral CPS or SPS therapy for 4 weeks. 7 
Results After 4 week-treatments, there was no significant difference of changes in 8 
serum potassium (K) from the baseline (ΔK) between the two groups. However, SPS 9 
significantly decreased serum calcium (Ca) and magnesium (Mg) and increased intact 10 
parathyroid hormone (iPTH) values, whereas CPS reduced iPTH. ΔiPTH was inversely 11 
correlated with ΔCa and ΔMg (r=-0.53 and r=-0.50, respectively). Furthermore, sodium 12 
(Na) and atrial natriuretic peptide (ANP) levels were significantly elevated in patients 13 
with SPS, but not with CPS, whereas ΔNa and ΔANP were significantly correlated with 14 
each other in all the patients. We also found that ΔNa and Δ(Na to chloride ratio) were 15 
positively correlated with ΔHCO3-. In artificial colon fluid, CPS increased Ca and 16 
decreased Na. Furthermore, SPS more decreased K, Mg, and NH3. Conclusion 17 
Compared with SPS, CPS may be safer for the treatment of hyperkalemia in pre-dialysis 18 
patients, because it did not induce hyperparathyroidism or volume overload.  19 
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Introduction  1 
Hyperkalemia is one of the most common complications in end-stage renal disease 2 
patients, and could cause serious electronic abnormality in the heart such as cardiac 3 
arrhythmias, thereby being involved in heart failure and sudden death in patients with 4 
advanced chronic kidney disease (CKD) [1]. Indeed, it has been reported that higher 5 
serum potassium (K) levels are associated with the increased risk of mortality in both 6 
CKD and non-CKD patients [2, 3]. Although there is a growing body of evidence that 7 
renin-angiotensin system (RAS) inhibitors have protected against the progression of 8 
renal disease and its associated organ damage in patients with advanced CKD [4, 5], the 9 
therapeutic option may be limited due to considerable side effects, such as hyperkalemia 10 
[6, 7]. Therefore, strict management of hyperkalemia is desirable for a wide variety of 11 
CKD patients to prevent adverse cardio-renal events [8, 9]. 12 
Polystyrene sulfonate (PS), a cation-exchange resin, is the most commonly 13 
used drug for the treatment of hyperkalemia [10, 11]. There are two types of PS, 14 
calcium (Ca) and sodium (Na) PS (CPS and SPS), which are cross-linked polymers to 15 
which reactive sulfonic groups are attached and preloaded with Ca and Na, respectively 16 
[12, 13]. Although both types of PS exchange their bound cations for K in the lumen of 17 
proximal and distal colon and resultantly reduce serum K levels through the excretion of 18 
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K into the stool, as far as we know, there is no head-to-head comparison prospective 1 
study of CPS vs. SPS in pre-dialysis CKD patients. 2 
Hypocalcemia and secondary hyperparathyroidism are also prevalent in 3 
advanced CKD patients [14, 15], both of which are associated with vascular 4 
calcification and osteoporotic bone fracture [16, 17], partly contributing to the increased 5 
risk of cardiovascular disease in these patients [18, 19]. Moreover, exposure to 6 
Na-containing formulations of medicines has been shown significantly to increase the 7 
risk of cardiovascular events in humans compared with standard formulations of those 8 
same drugs [20, 21]. Therefore, in this study, we performed an open-labeled, 9 
randomized, prospective, and crossover trial to directly compare the effects of CPS and 10 
SPS on mineral and bone metabolism, including serum K, Ca, phosphate (P), 11 
magnesium (Mg), intact parathyroid hormone (iPTH) and Na levels in 20 pre-dialysis 12 
outpatients (estimated glomerular filtration rate (eGFR)<30ml/min/1.73m2) with 13 
hyperkalemia (serum K>5.0mmol/l). We further examined the effects of CPS and SPS 14 
on plasma natriuretic peptide (ANP) levels in our patients and investigated whether 15 
change of ANP after PS treatments (ΔANP) was correlated with that of ΔNa. 16 
 17 
Materials and methods 18 
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Patients 1 
A total of 20 pre-dialysis CKD 4-5 outpatients with hyperkalemia (K>5 mmol/l) not 2 
treated with PS were enrolled in this study. The patients were followed-up at Kurume 3 
University Hospital, Oita Prefectural Hospital, and Munakata Suikokai General Hospital 4 
from October 2013 to November 2014. We excluded patients who were already given 5 
PSs, who had acute kidney injury. The etiology of renal disease was as follows: diabetic 6 
nephropathy (n=6), glomerulonephritis (n=5), nephrosclerosis (n=3), lupus nephritis 7 
(n=2), membranous nephropathy (n=1), IgA nephropathy (n=1), and unknown (n=2). 8 
More than a half of the patients received RAS inhibitors and Ca blockers for the 9 
treatment of hypertension (55 %, 65 %, respectively). No patients received diuretics or 10 
phosphate binders during the study period.  11 
  12 
Study design 13 
This study was designed as a prospective, open-labeled, randomized, and crossover 14 
study (Fig. 1). Twenty hyperkalemic patients were randomly assigned to CPS group 15 
(n=10) or SPS group (n=10) by an envelope method. Patients were orally administered 16 
CPS (ARGAMATE® 89.29 % GRANULE 5.6 g; powder 5 g) or SPS (KAYEXALATE 17 
DRY SYRUP 76%® 6.54 g; powder 5 g) after each meal. After 4 weeks treatment 18 
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(period 1), each PS was immediately switched to another PS without washout interval, 1 
and followed-up for further 4 weeks (period 2). Blood pressure was measured in the 2 
sitting position using an upright standard sphygmomanometer.  3 
 4 
Data collection 5 
Before and after the switching to PS, blood was drawn from antecubital veins for 6 
determination of serum blood urea nitrogen, creatinine, K, albumin, Ca, P, Mg, Na, 7 
ammonia (NH3), iPTH, and plasma ANP. Urine was collected for evaluation of urinary 8 
K and Na excretion levels. Blood and urine chemistries were measured at a 9 
commercially available laboratory (SRL Inc., Hachioji, Japan) as described previously 10 
[22]. We calculated corrected Ca levels by the following of Ca correction formula 11 
(Payne): Ca (mg/dl)+(4-serum albumin(g/dl)) [23]. Venous blood gas was taken to 12 
analyze the plasma bicarbonate (HCO3-) levels [24].  13 
 14 
In vitro study  15 
To investigate the cation-absorption capacity of CPS and SPS, we constructed an 16 
artificial colon fluid (ACF) based on the data of human diarrhea as described previously 17 
[25]. One gram of CPS or SPS was added into the 50 ml of ACF (n=6, respectively) and 18 
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the solution were stirred at room temperature for 120 minutes. After filtration, the 1 
concentrations of K, Ca, Na, Mg, and NH3 in the supernatant were determined. 2 
 3 
Statistical analysis 4 
Unless otherwise, data were expressed as mean±SD. Distribution of iPTH is, in general, 5 
heavily skewed, therefore, data on iPTH was presented as the median value 6 
[interquartile range]. A one-way analysis of variance for repeated measures was used to 7 
assess the differences in baseline characteristics. To examine the difference of serum K, 8 
Ca, P, Na, chloride (Cl), Mg, iPTH, and ANP levels before and after the treatment with 9 
CPS or SPS in the period 1 and period 2, a paired t-test was performed. Unpaired t-test 10 
was performed in the comparison between CPS (n=20) and SPS (n=15) group. A 11 
Wilcoxon rank sum test and a Mann-Whitney U test were used for within group 12 
differences and between group differences of serum iPTH, respectively. All statistical 13 
analyses were performed by Graph Prism 5.0 for windows (GraphPad Software Inc. La 14 
Jolla, CA, USA) except for stepwise multiple regression analysis, which was performed 15 
to explore the independent determinants of ΔiPTH using IBM SPSS statistics ver.20 16 
(IBM, Chicago, IL, USA). Statistical significance was defined as p<0.05. 17 
 18 
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Results  1 
Clinical characteristics of the patients 2 
Clinical characteristics of 20 pre-dialysis outpatients with hyperkalemia are shown in 3 
Table 1. Overall, 55 % of the patients were women and mean age was 69.7±11.5 years 4 
old. Six patients (30 %) had diabetes mellitus. The mean eGFR was 15.9±5.9 5 
ml/min/1.73m2 and 45 % had an eGFR<15 ml/min/1.73m2. The mean serum K levels 6 
were 5.50±0.51 mmol/l. Nutritional conditions of all subjects were almost normal. 7 
There was no significant difference of clinical data between the two groups at baseline. 8 
Medications except PS were not changed during the study period. As shown in Fig.1, 5 9 
patients treated with SPS dropped out due to drug-related adverse events, such as edema 10 
(3 patients), headache (1 patient), and diarrhea (1 patient). 11 
 12 
Effects of CPS and SPS on serum and urinary levels of K  13 
We examined serum K levels before and after the CPS and SPS treatments in period 1 14 
(n=10, respectively). As shown in Table 2, serum K and urinary K corrected for urinary 15 
creatinine (Cr) values were significantly decreased by both treatments. The change in 16 
serum K and urinary K/Cr from baseline (serum and urinary ∆K) was almost equal 17 
between the CPS and SPS group.  18 
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 1 
Effects of CPS and SPS on other mineral and bone metabolism 2 
We next examined whether CPS or SPS treatment could affect serum Ca, P, Mg, and 3 
iPTH levels in our patients. As shown in Table 3, although, serum P levels were not 4 
affected by either PS treatment, SPS, but not CPS treatment significantly decreased 5 
serum Ca and Mg levels. Furthermore, SPS treatment significantly increased serum 6 
iPTH levels, whereas CPS decreased it. In univariate linear regression analysis, ΔCa 7 
and ΔMg were positively associated with ΔiPTH values during the period 1 and 2 (n=35, 8 
r=-0.53, p<0.001 and r=-0.50, p<0.01, respectively) (Figs. 2a and b). Stepwise multiple 9 
regression analysis revealed that ΔCa (adjusted β=-0.33, p<0.05), ΔMg (adjusted 10 
β=-0.37, p<0.01), and ΔP (adjusted β=0.35, p<0.05) were independent determinants of 11 
ΔiPTH values in our patients (Table 4). Multicollinearity in these three values was not 12 
recognized.  13 
 14 
Effects of CPS and SPS on serum and urinary Na, plasma ANP, and acid-base 15 
equilibrium  16 
We further investigated whether the administration of CPS or SPS could affect serum 17 
and urinary Na and plasma ANP levels. As shown in Table 5, serum Na levels were 18 
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significantly increased by SPS treatment, whereas decreased by CPS. Urinary Na/Cr 1 
values were modestly, but not significantly increased by SPS, whereas decreased by 2 
CPS (Table 5). Moreover, SPS, but not CPS treatment significantly increased plasma 3 
ANP levels. In univariate linear regression analysis, ΔNa was positively associated with 4 
ΔANP values during the period 1 and 2 (Fig. 2c). Mean blood pressure and body weight 5 
were tended to increase by SPS treatment (95.3±17.5 to 97.5±13.4 mmHg, p=0.14, 6 
54.6±13.1 to 55.0±12.8 kg, p=0.33, respectively). There was a positive correlation 7 
between ΔNa and Δbody weight (p<0.05, r=0.45, n=20) (Fig. 2d). 8 
It has been reported that SPS induces metabolic alkalosis via the absorption of NH3 in 9 
the colon fluid [26]. So, we next compared the effects of SPS on serum NH3 and plasma 10 
bicarbonate (HCO3-) levels with those of CPS (Table 5). SPS, but not CPS treatment 11 
significantly increased plasma HCO3- and serum Na levels, while serum NH3 levels 12 
were not changed by either PS treatment. As shown in Figs. 3a-c, ΔNa and Δ(Na to Cl 13 
ratio) but not ΔNH3 were positively correlated with ΔHCO3- (r=0.75, p<0.0001, r=0.84, 14 
p<0.0001, and r=0.06, p=0.75, respectively).  15 
 16 
Effects of CPS or SPS on cation exchange capacity in ACF  17 
As shown in Table 6, K levels in the ACF were significantly decreased by CPS or SPS; 18 
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the effect of the latter was larger than that of the former. CPS and SPS had opposite 1 
effects on Ca and Na levels in the ACF; CPS increased Ca and decreased Na, and SPS 2 
vice versa. Furthermore, SPS treatment more decreased Mg and NH3. 3 
 4 
Discussion  5 
In our human study, although K-decreasing capacity of CPS and SPS was almost equal, 6 
serum Ca and Mg levels were significantly decreased by SPS treatment compared with 7 
CPS. These findings are consistent with the previous report showing that CPS did not 8 
affect serum Ca or Mg levels in patients with chronic renal failure [10]. Furthermore, in 9 
this study, SPS treatment significantly increased iPTH levels, whereas CPS decreased it. 10 
There was a significant and independent correlation between ΔCa or ΔMg and ΔiPTH 11 
values. Since SPS more exchanged their bound Na for K, Mg, Ca, and NH3 in the ACF, 12 
higher cations-exchanging capacity of SPS could be involved in lower serum levels of 13 
Ca and Mg, thereby worsening secondary hyperparathyroidism. In addition, although 14 
there was no significant difference of serum NH3 between the two groups, SPS may 15 
increase intraluminal pH by absorbing NH3. Because higher intestinal pH has been 16 
reported to inhibit an activity of TRPM6, a major transporter of Mg in the colon [27], 17 
which could suppress the absorption of Mg, it might partly contribute to the decrease in 18 
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serum Mg levels by SPS. 1 
Parathyroid cells have calcium-sensing receptors (CaRs) on cell-surface, which enable 2 
them to respond to changes in extracellular Ca concentration [28, 29]. Although Ca is 3 
the main CaR agonist, Mg is also able to activate the CaRs [30]. An increased 4 
extracellular Mg has been shown to inhibit PTH secretion by parathyroid cells [31]. 5 
Low Ca, low Mg, or high iPTH levels are associated with progression of diabetic 6 
kidney disease [32] and cardiovascular mortality in patients with dialysis [33]. So our 7 
present findings may raise the safety concern of SPS for the treatment of hyperkalemia 8 
in pre-dialysis patients due to its detrimental effects of Ca, Mg, and iPTH [18]. On the 9 
other hand, since a meta-analysis revealed that calcium supplements were associated 10 
with an increased risk of myocardial infarction [34], Ca load by CPS may also increase 11 
the risk of vascular calcification and cardiovascular events in CKD patients. Therefore, 12 
excess Ca intake and Ca-based phosphate binders may be avoided in CKD patients, 13 
especially those with vascular calcification. 14 
In this study, we also found that serum Na and plasma ANP levels were significantly 15 
elevated by the treatment with SPS. Further, ΔNa was positively correlated with ΔANP 16 
values during the study (Fig. 2c). The changes in serum Na concentration are 17 
determined not only by intestinal Na absorption, but also by water intake. Although we 18 
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did not evaluate water intake in our patients, there was a positive correlation between 1 
ΔNa and Δbody weight (p<0.05, r=0.45, n=20) (Fig.2d), thus suggesting that the 2 
increase of Na level by SPS might be associated with increased extracellular fluid. 3 
Recent retrospective study has shown that SPS causes inter-dialytic weight gain and 4 
increases blood pressure in dialysis patients in Dialysis Outcomes and Practice Patterns 5 
Study [35]. Exposure to sodium-containing formulations of drugs are associated with 6 
adverse cardiovascular events in patients compared to sodium-free formulation ones 7 
[20]. Therefore, intake of sodium should be strictly controlled in patients who were 8 
receiving SPS.  9 
In the present study, although K-exchanging capacity of SPS was higher than that of 10 
CPS, serum K-reducing ability of both drugs was nearly the same. It has been reported 11 
that K concentration in lower intestine was higher than that in upper one, and the 12 
highest in distal colon [36, 37]. SPS has mainly absorbed K, Mg, Ca, and NH3 in the 13 
fluid of upper digestive tract, where K concentration is low. On the other hand, CPS has 14 
absorbed K in the distal colon rather than upper digestive tract due to the lower 15 
cation-exchange capacity, where K concentration is highest. This might be a possible 16 
reason for the discrepant results between ACF experiments and pre-dialysis patients.  17 
Treatment of SPS has been reported to increase HCO3- levels due to absorption of NH3 18 
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in the digestive tract [26]. Consistent with the previous reports, we found that SPS, but 1 
not CPS, dramatically increased plasma HCO3- levels. Furthermore, although ΔNH3 2 
was not associated with ΔHCO3- values, ΔNa and Δ(Na to Cl ratio) were positively 3 
correlated with ΔHCO3-. A close relationship between sodium as well as potassium 4 
balance and renal response to a chronic acid load was first reported in 1977 [38]. 5 
Further, Lindner et al. have shown that rising serum Na levels could cause a concurrent 6 
development of metabolic alkalosis in critically ill patients [39]. Recently Stewart 7 
approach is proposed as a new idea of acid-base equilibrium [40, 41]. 8 
There are several limitations in this study. First, the sample size was small and the study 9 
duration was short. Second, due to the ethical concern, we could not set a washout 10 
period in this crossover study. Furthermore, as many as 5 patients were dropped out 11 
during the phase of SPS. Impaired capacity of electrolyte excretion by the kidney may 12 
affect the present findings. 13 
 14 
Conclusion 15 
In summary, although the present study demonstrated that K-reducing capacity of CPS 16 
and SPS was almost equal in pre-dialysis CKD patients with hyperkalemia, SPS 17 
treatment decreased Ca and Mg levels in association with increase in serum iPTH, Na, 18 
Nakayama et al.  
15 
 
or plasma ANP values, which might lead to hyperparathyroidism and volume overload. 1 
Our present findings suggest that CPS might be better than SPS to control hyperkalemia 2 
in pre-dialysis patients. Further longitudinal studies are needed to clarify whether CPS 3 
treatment could exert more beneficial effects on bone metabolism and cardiovascular 4 
events in advanced CKD patients compared with SPS. 5 
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Figure Legends   5 
Fig. 1 Study design. CKD patients were randomized to CPS and SPS groups. After the 6 
first 4 weeks of the therapy phase (period 1, n=20), CPS and SPS were immediately 7 
switched to another PS, and followed for further 4 weeks (period 2, n=35). CKD, 8 
chronic kidney disease; PS, polystyrene sulfonate; CPS, calcium polystyrene sulfonate; 9 
SPS, sodium polystyrene sulfonate. 10 
 11 
Fig. 2 Pearson’s correlation between (a) ΔiPTH and ΔCa, (b) ΔiPTH and ΔMg, (c) 12 
ΔANP and ΔNa (n=35, respectively), and (d) Δbody weight and ΔNa (n=20). Δ, 13 
changes the values from the baseline or period 1; iPTH, intact parathyroid hormone; Ca, 14 
calcium; Mg, magnesium; Na, sodium; ANP, atrial natriuretic peptide.  15 
 16 
Fig. 3 Pearson’s correlation between (a) ΔHCO3- and ΔNa, (b) ΔHCO3- and ΔNa to Cl 17 
ratio, and (c) ΔHCO3- and ΔNH3 (n=35, respectively). Δ, changes the values from the 18 
baseline or period 1; HCO3-, bicarbonate; NH3, ammonia; Na, sodium; Cl, chloride.  19 
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Table 1 Baseline characteristics of the study population  
Variables Total (n=20) CPS (n=10) SPS (n=10) p 
Age (years) 
Female No. (%) 
Diabetes No. (%) 
BMI(kg/m2) 
Body weight (kg) 
Mean BP (mmHg) 
eGFR(ml/min/1.73m2) 
Serum Cr (mg/dl) 
Serum BUN (mg/dl) 
Serum albumin (g/dl) 
Serum Na (mmol/l) 
Serum K (mmol/l) 
Serum Cl (mmol/l) 
Serum Ca (mg/dl) 
Serum P (mg/dl) 
Serum Mg (mg/dl) 
Serum NH3 (μg/dl) 
Plasma ANP (pg/ml) 
Plasma HCO3- 
(mmol/l) 
Urinary K/Cr (g/ gCr) 
Urinary Na/Cr (g/ gCr) 
Serum iPTH (pg/ml) 
Medications No. (%) 
RAS inhibitors 
Ca-blockers 
α, β-blockers 
Mg oxide 
Sodium bicarbonate 
69.7±11.5 
11 (55) 
6 (30) 
21.9±3.1 
54.7±12.2 
91.4±14.0 
15.9±5.9 
3.19±1.35 
48.8±16.9 
3.97±0.38 
140.8±2.1 
5.50±0.51 
109.6±3.2 
9.11±0.36 
4.08±0.65 
2.16±0.41 
52.3±11.3 
70.3±68.0 
21.5±2.9 
1.6±0.8 
3.2±1.6 
154 [106, 253 (147)] 
 
11 (55) 
13 (65) 
6 (30) 
2 (10) 
6 (30) 
69.1±12.0 
6 (60) 
4 (40) 
21.4±3.0 
51.9±12.5  
89.7±14.2 
13.0±4.7 
3.79±1.61 
53.8±21.0 
3.90±0.44 
140.8±2.0 
5.39±0.49 
109.4±3.2 
9.20±0.29 
4.03±0.54 
2.19±0.29 
54.2±12.0 
70.8±49.3 
20.6±2.2 
1.4±0.6 
3.2±1.8 
188 [111, 313 (202)] 
 
8 (80) 
7 (70) 
5 (50) 
1 (10) 
3 (30) 
70.2±11.7 
5 (50) 
2 (20) 
22.4±3.3 
57.8±11.8 
93.2±14.6 
18.7±5.7 
2.59±0.68 
45.8±11.2 
4.04±0.32 
140.8±2.2 
5.60±0.54 
109.7±3.2 
9.01±0.41 
4.13±0.76 
2.13±0.53 
50.1±10.6 
69.9±85.7 
22.4±3.3 
1.8±1.0 
3.3±1.5 
135 [86, 233(147)] 
 
3 (30) 
6 (60) 
1 (10) 
1 (10) 
3 (30) 
0.98 
0.91 
0.64 
0.78 
0.62 
0.88 
0.08 
0.13 
0.57 
0.72 
0.99 
0.66 
0.98 
0.51 
0.94 
0.95 
0.74 
0.99 
0.37 
0.60 
0.99 
0.49 
Categorical and continuous values are expressed as % and mean±SD or median [interquartile range], 
respectively. A one-way analysis of variance for repeated measures was used to assess the difference 
of baseline characteristics. CPS, calcium polystyrene sulfonate; SPS, sodium polystyrene sulfonate; 
BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; Cr, 
creatinine; BUN, blood urea nitrogen; Na, sodium; K, potassium; Cl, chloride; Ca, calcium; P, 
phosphate; Mg, magnesium; NH3, ammonia; ANP; atrial natriuretic peptide; HCO3-, bicarbonate; 
iPTH, intact parathyroid hormone; RAS, renin-angiotensin system.               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Effects of CPS and SPS treatment on serum and urinary K levels  
Serum K (mmol/l) 0week 4weeks ∆serum K (95% C.I.) p 
CPS (n=10) 5.39±0.49 4.14±0.91 -1.25 (-1.90 to -0.60) p<0.01 
SPS (n=10) 5.60±0.54 4.12±0.64 -1.48 (-1.88 to -1.08) p<0.0001 
p 0.37 0.96 0.51  
Urinary K/Cr 
(g/ gCr) 
0week 4weeks 
∆urinary K/Cr  
(95% C.I.) 
p 
CPS (n=10) 1.39±0.58 0.76±0.25 -0.62 (-0.99 to -0.25) p<0.01 
SPS (n=10) 1.75±0.96 1.01±0.63 -0.73 (-1.34 to -0.13) p<0.05 
p 0.32 0.26 0.72  
K levels were compared only with before and after PS treatment in period 1 (n=10, respectively). 
Values are expressed as mean±SD. Statistical significance was determined using a paired t-test 
(within group differences). Statistical significance was determined using an unpaired t-test (between 
group differences). ∆, change values from the baseline; K, potassium; Cr, creatinine; CPS, calcium 
polystyrene sulfonate; SPS, sodium polystyrene sulfonate; period 1, after first 4 weeks of therapy 
phase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Effects of CPS and SPS treatment on mineral and bone metabolism 
Serum Ca (mg/dl) 0week 4weeks ∆Ca (95% C.I.) p 
CPS (n=20) 8.96±0.46 9.09±0.52 0.13 (-0.10 to 0.36) 0.26 
SPS (n=15) 9.09±0.37 8.77±0.47 -0.33 (-0.54 to -0.11) p<0.01 
p 0.37 0.07 p<0.01  
Serum P (mg/dl) 0week 4weeks ∆P (95% C.I.) p 
CPS (n=20) 3.96±1.04 3.79±0.73 -0.17 (-0.44 to 0.10) 0.20 
SPS (n=15) 3.99±0.69 4.04±1.36 0.04 (-0.55 to 0.64) 0.86 
p 0.90 0.48 0.44  
Serum Mg (mg/dl) 0week 4weeks ∆Mg (95% C.I.) p 
CPS (n=20) 2.03±0.46 2.13±0.34 0.11 (-0.01 to 0.22) 0.07 
SPS (n=15) 2.17±0.45 1.93±0.48 -0.23 (-0.32 to -0.15) p<0.001 
p 0.37 0.16 p<0.001  
Serum iPTH 
(pg/ml) 
0week 4weeks  
∆iPTH  
[interquartile range] 
p 
CPS (n=20) 
171  
[118, 255 (137)] 
122 
[71, 224 (153)] 
-52 
[-93, 3 (96)] 
p<0.01 
SPS (n=15) 
118 
[75, 229 (154)] 
173 
[129, 244(115)] 
80 
[-22, 120 (142)] 
p<0.05 
p 0.15 0.08 p<0.001  
Values are expressed as mean±SD. Serum iPTH levels were expressed as median [interquartile 
range]. Statistical significance was determined using a paired t-test (within group differences) for 
serum Ca, P, and Mg. A Wilcoxon rank sum test (within group differences) and a Mann-Whitney U 
test (between group differences) were performed for serum iPTH. Ca, calcium; P, phosphate; Mg, 
magnesium; iPTH, intact parathyroid hormone; ∆, change values from the baseline or period 1; C.I., 
confidence internal; CPS, calcium polystyrene sulfonate; SPS, sodium polystyrene sulfonate.  
 
 
 
 
 
Table 4 Stepwise multiple regression analysis for ∆iPTH in pre-dialysis patients with PS treatment  
 
Unadjusted (β, p) 
r2=0.28 
Model 1 (β, p) 
r2=0.39 
Model 2 (β, p) 
r2=0.50 
∆Ca -0.53 (p<0.001) -0.41 (p<0.01) -0.33 (p<0.05) 
∆Mg  -0.35 (p<0.05) -0.37 (p<0.01) 
∆P   0.35 (p<0.05) 
Stepwise multiple regression analysis was performed for the independent determinants of ∆iPTH 
(n=35). Pearson’s correlation coefficient (r) and the regression line are presented. Multicollinearity 
was not recognized (tolerance ∆Mg=0.86 and ∆P=0.97). β, standardized coefficient; ∆, change 
values from the baseline (n=20) or period 1 (n=15); iPTH, intact parathyroid hormone; Ca, calcium; 
Mg, magnesium; P, phosphate; PS, polystyrene sulfonate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 5 Effects of CPS and SPS treatment on sodium loading and acid-base equilibrium 
Serum Na (mmol/l) 0week 4weeks ∆Na (95% C.I.) p 
CPS (n=20) 142±2.7 141±2.8 -1.25 (-2.33 to 0.17) p<0.05 
SPS (n=15) 141±2.0 143±2.7 2.07 (0.99 to 3.14) p<0.001 
p 0.19 p<0.05 p<0.001  
Urinary Na/Cr 
(g/ gCr) 
0week 4weeks 
∆urinary Na/Cr 
 (95% C.I.) 
p 
CPS (n=20) 4.1±3.0 3.0±1.4 -1.1±2.7 (-2.4 to 0.2) 0.09 
SPS (n=15) 3.4±1.4 5.0±3.2 1.6±3.5 (-0.3 to 3.5) 0.10 
p 0.38 p<0.05 p<0.05  
Serum Cl (mmol/l)  0week 4weeks ∆Cl (95% C.I.) p 
CPS (n=20) 108±3.7 109±4.2 1.00 (-0.86 to 2.86) 0.27 
SPS (n=15) 109±3.5 106±4.4 -3.13 (-4.40 to -1.86) p<0.001 
p 0.33 0.06 p<0.01  
Plasma ANP (pg/ml) 0week 4weeks ∆ANP (95% C.I.) p 
CPS (n=20) 93±81 79±68 -14.0 (-36.7 to 8.8) 0.21 
SPS (n=15) 80±76 113±92 36.2 (11.1 to 61.2) p<0.01 
p 0.60 0.22 p<0.01  
Serum Na to Cl ratio 0week 4weeks ∆Na to Cl ratio (95% C.I.) p 
CPS (n=20) 1.32±0.05 1.29±0.04 -0.02 (-0.05 to -0.0) p<0.05 
SPS (n=15) 1.29±0.04 1.35±0.05 0.06 (0.04 to 0.07) p<0.0001 
p 0.11 p<0.001 p<0.0001  
Plasma HCO3- 
(mmol/l) 
0week 4weeks ∆HCO3- (95% C.I.) p 
CPS (n=20) 23.4±4.1 20.9±3.6 -2.5 (-3.7 to -1.3) p<0.001 
SPS (n=15) 21.2±3.2 25.9±4.1 4.2 (2.8 to 5.6) p<0.0001 
p 0.07 p<0.001 p<0.0001  
Serum NH3 (μg/dl) 0week 4weeks ∆NH3 (95% C.I.) p 
CPS (n=20) 55±12 54±12 -0.6 (-6.0 to 4.8) 0.82 
SPS (n=15) 53±12 54±11 2.4 (-7.1 to 11.9) 0.59 
p 0.67 0.97 0.53  
Values are expressed as mean±SD. Statistical significance was determined using a paired t-test 
(within group differences). Statistical significance was determined using an unpaired t-test (between 
group differences). The data were in serum, urinary and plasma samples. ∆, change values from the 
baseline or period 1; C.I., confidence internal; Na, sodium; Cr, creatinine; Cl, chloride; ANP, atrial 
natriuretic peptide; HCO3-, bicarbonate; NH3, ammonia; CPS, calcium polystyrene sulfonate; SPS, 
sodium polystyrene sulfonate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6 Effects of CPS and SPS treatment on K, Ca, Mg, Na, and NH3 concentrations in ACF 
ACF K (mmol/l) Before after ∆K (95% C.I.) p 
CPS (n=6) 8.83±0.08 7.60±0.15 -1.23 (-1.32 to -1.15) p<0.0001 
SPS (n=6) 8.87±0.10 6.80±0.13 -2.07 (-2.24 to -1.90) p<0.0001 
p 0.55 p<0.0001 p<0.0001  
ACF Ca (mg/dl) Before after ∆Ca (95% C.I.) p 
CPS (n=6) 19.5±0.19 85.5±2.13 66.0 (63.8 to 68.2) p<0.0001 
SPS (n=6) 19.5±0.23 5.51±0.15 -14.0 (-14.3 to -13.8) p<0.0001 
p 0.69 p<0.0001 p<0.0001  
ACF Mg (mg/dl) before after ∆Mg (95% C.I.) p 
CPS (n=6) 11.9±0.47 8.92±0.25 -3.0 (-3.3 to -2.6) p<0.0001 
SPS (n=6) 11.7±0.57 5.57±0.25 -6.1 (-6.5 to -5.7) p<0.0001 
p 0.52 p<0.0001 p<0.0001  
ACF Na (mmol/l) before after ∆Na (95% C.I.) p 
CPS (n=6) 149±2.04 141±3.62 -8.17 (-9.8 to -6.5) p<0.0001 
SPS (n=6) 150±2.58 213±13.8 63.0 (50.3 to 75.7) p<0.0001 
p 0.55 p<0.0001 p<0.0001  
ACF NH3 (μg/dl) before after ∆NH3 (95% C.I.) p 
CPS (n=6) 14.0±0.13 12.8±0.17 -1.23 (-1.40 to -1.06) p<0.0001 
SPS (n=6) 14.0±0.16 11.7±0.31 -2.34 (-2.67 to -2.01) p<0.0001 
p 0.67 p<0.0001 p<0.0001  
Values are expressed as mean±SD. Statistical significance was determined using a paired t-test 
(within group differences). Statistical significance was determined using an unpaired t-test (between 
group differences). The data were in ACF and ACF plus each polystyrene sulfonates (CPS 1g 
treatment, n=6 or SPS 1g treatment, n=6). ACF, artificial colon fluid; ∆, change values from the 
before PS treatment; C.I., confidence internal; K, potassium; Ca, calcium; Mg, magnesium; Na, 
sodium; NH3, ammonia; PS, polystyrene sulfonate; CPS, calcium polystyrene sulfonate; SPS, 
sodium polystyrene sulfonate. 
 
